



February 26, 2018

Amyris to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15, 2018

EMERYVILLE, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the fourth quarter and fiscal year ended December 31, 2017 after market close on Thursday, March 15, 2018. The company noted that it has completed fiscal 2017 above expectations and expects to report anticipated unaudited full-year revenue above the high end of the company's prior anticipated annual revenue outlook of \$130-132 million and with gross margin to significantly exceed the stated 2017 target of above 50 percent for the company. As a result of closing a significant transaction with DSM late in December 2017, Amyris noted that it requires additional time to complete customary year-end closing procedures prior to reporting financial results.

The company will hold its quarterly conference call to discuss these results, as well as provide an update on the company's business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, March 15, 2018.

Conference Call:

Thursday, March 15, 2018, 4:30 p.m. ET/1:30 p.m. PT

Dial-in Number:

(866) 516-3867 (U.S. & International)

Access Code: 8249169

Audio Webcast:

A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit:

<http://investors.amyris.com>. A replay of the webcast will be available on the [Investor Relations](#) section of the company's website approximately two hours after the conclusion of the call.

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the reporting of anticipated unaudited full-year 2017 revenue and gross margin), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to adjustments to unaudited full-year 2017 revenue and gross margin resulting from the completion of year-end closing procedures, as well as other adjustments and developments that may arise prior to finalizing full-year 2017 financial results, including as a result of the audit of Amyris's full-year 2017 financial results, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Contact:

Peter DeNardo

Director, Investor Relations and Corporate Communications

Amyris, Inc.

+1 (510) 740-7481

investor@amyris.com
pr@amyris.com